What is the recommended antimicrobial therapy for Enterococcus faecalis bacteraemia, including drug choice, dosing, and duration?

Ampicillin or Amoxicillin is the Drug of Choice for Enterococcus faecalis Bacteraemia

For ampicillin-susceptible E. faecalis bacteraemia, treat with ampicillin 200 mg/kg/day IV in 4-6 divided doses (or amoxicillin at equivalent dosing) for 7-14 days in uncomplicated cases, or 4-6 weeks if endocarditis is present. 1

Drug Selection Algorithm

First-Line Therapy (Ampicillin-Susceptible Strains)

Monotherapy is appropriate for uncomplicated bacteraemia:

• Ampicillin 2g IV every 4 hours (or amoxicillin 200 mg/kg/day in 4-6 divided doses) 2
• This is superior to vancomycin—glycopeptide use is independently associated with 2.5-fold increased 30-day mortality compared to beta-lactams 3
• Recent research confirms amoxicillin use is associated with better outcomes in multivariate analysis 4

Combination therapy is reserved for specific situations:

• Add gentamicin 3 mg/kg/day IV in 1 dose for endocarditis (2-6 weeks depending on clinical scenario) 2
• The role of combination therapy for bacteraemia WITHOUT endocarditis remains unresolved and is not routinely recommended 1
• Recent 2026 data shows no benefit of combination therapy over monotherapy for E. faecalis BSI without endocarditis (28% vs 36% clinical failure, p=0.185) 5

Alternative Regimens

For high-level aminoglycoside resistance (HLAR):

• Ampicillin 200 mg/kg/day + ceftriaxone 4g/day IV in 2 doses for 6 weeks 2
• This combination is active against E. faecalis with and without HLAR, making it the combination of choice for HLAR E. faecalis endocarditis 2
• Associated with similar cure rates but fewer adverse events (particularly nephrotoxicity) compared to aminoglycoside-containing regimens 6
• Critical caveat: This combination is NOT active against E. faecium 2

For ampicillin-resistant strains:

• Vancomycin 30 mg/kg/day IV in 2 doses 1
• Target trough levels 10-14 mg/L for E. faecalis (or AUC 370-540 mg·h/L) 7
• If combining with gentamicin for endocarditis, use 6 weeks of both agents 2

For vancomycin-resistant strains:

• Linezolid or daptomycin based on susceptibility 1
• For daptomycin: use high-dose (≥8-10 mg/kg/day) 8, 9
• Consider daptomycin 10 mg/kg/day + ampicillin 200 mg/kg/day for multidrug-resistant strains 2

Duration of Therapy

Uncomplicated bacteraemia (no endocarditis):

• 7-14 days if catheter removed or retained with antibiotic lock 1
• Recent data supports even shorter courses (<7 days) for catheter-related BSI in selected uncomplicated cases after device removal 10

Endocarditis:

• Native valve: 4-6 weeks (4 weeks if symptoms <3 months, 6 weeks if >3 months or prosthetic material) 11, 6
• Prosthetic valve: minimum 6 weeks 2, 11

Sequential oral therapy:

• Emerging evidence suggests sequential oral therapy may be noninferior to IV-only treatment for E. faecalis BSI 12
• Consider in clinically stable patients without endocarditis after initial IV therapy
• Requires appropriate oral agent with documented efficacy and patient able to absorb medication 8

Critical Management Points

Mandatory echocardiography indications:

• New murmur or embolic phenomena
• Persistent bacteraemia/fever >72 hours despite appropriate therapy
• Prosthetic valve or endovascular foreign body present 1
• Risk of endocarditis with enterococcal catheter-related BSI is relatively low (1.5%) but must be excluded 1

Source control:

• Remove short-term catheters 1
• Remove long-term catheters if: insertion site infection, suppurative thrombophlebitis, sepsis, endocarditis, persistent bacteraemia, or metastatic infection 1
• If catheter retained, use antibiotic lock therapy plus systemic therapy 1
• Remove catheter if bacteraemia persists >72 hours after appropriate antibiotics 1

Monitoring:

• Follow-up blood cultures to confirm clearance, especially if catheter retained
• Monitor renal function and gentamicin levels weekly (twice weekly in renal failure) if aminoglycosides used 2
• Assess clinical response using inflammatory markers and clinical trends rather than routine follow-up cultures in responding patients 10

Common Pitfalls to Avoid

1. Using vancomycin when ampicillin is appropriate—this significantly increases mortality risk 3
2. Routine use of combination therapy for uncomplicated bacteraemia—adds toxicity without proven benefit 5
3. Using ampicillin-ceftriaxone for E. faecium—this combination is ineffective against E. faecium 2
4. Inadequate duration of aminoglycoside in endocarditis—unlike streptococcal IE, enterococcal IE requires aminoglycoside for the entire treatment course (not just 2 weeks) when used 11
5. Failure to remove infected catheters—persistent bacteraemia mandates catheter removal 1